These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36915627)

  • 1. Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis.
    Gu X; Si J; Guan Y; Xu Y; Shao L; Zhang Y; Xu C; Pan W; Lu Y; Song Z; Wang W
    Open Med (Wars); 2023; 18(1):20230653. PubMed ID: 36915627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with rare
    Jiang H; Li Y; Wang Y; Zou B; Chen Y; Zhang Y; Husain H; Forest F; Qian F; Zhang L; Zhou C; Liu H; Wang D; Zhang W; Lu J; Han B
    Transl Lung Cancer Res; 2024 Jul; 13(7):1672-1684. PubMed ID: 39118889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer.
    Chen H; Huang D; Lin G; Yang X; Zhuo M; Chi Y; Zhai X; Jia B; Wang J; Wang Y; Li J; An T; Wu M; Wang Z; Zhao J
    Cancer Med; 2022 Oct; 11(19):3581-3592. PubMed ID: 35394121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
    Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
    Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
    [No Abstract]   [Full Text] [Related]  

  • 5. [Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].
    Guo LY; Xiang C; Zhao RY; Chen SN; Ma SJ; Han YC
    Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):117-123. PubMed ID: 36748130
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment patterns and outcomes in KRAS
    Barghout SH; Zhan LJ; Raptis S; Al-Agha F; Esfahanian N; Popovacki A; Kasymjanova G; Proulx-Rocray F; Chan SWS; Richardson M; Brown MC; Patel D; Dean ML; Navani V; Moore E; Carvery L; Yan E; Goldshtein D; Cleary-Gosine J; Gibson AJ; Hubley L; Balaratnam K; Ngo T; Gill A; Black M; Sacher A; Bradbury PA; Shepherd FA; Leighl N; Cheema P; Kuruvilla S; Agulnik J; Banerji S; Juergens R; Blais N; Cheung W; Wheatley-Price P; Liu G; Snow S
    Lung Cancer; 2024 Aug; 194():107898. PubMed ID: 39074423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of immunotherapy in
    Peng L; Guo J; Kong L; Huang Y; Tang N; Zhang J; Wang M; He X; Li Z; Peng Y; Wang Z; Han X
    Front Oncol; 2022; 12():1070761. PubMed ID: 36741723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy.
    Cefalì M; Epistolio S; Ramelli G; Mangan D; Molinari F; Martin V; Freguia S; Mazzucchelli L; Froesch P; Frattini M; Wannesson L
    J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutation predict response and outcome in advanced non-small cell lung carcinoma without driver alterations receiving PD-1 blockade immunotherapy combined with platinum-based chemotherapy: a retrospective cohort study from China.
    Li Q; Zhou Q; Zhao S; Wu P; Shi P; Zeng J; Xiong X; Chen H; Kittaneh M; Bravaccini S; Zanoni M; Zhou C; Zhang J
    Transl Lung Cancer Res; 2022 Oct; 11(10):2136-2147. PubMed ID: 36386464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Real-World Study in Advanced Non-Small Cell Lung Cancer with KRAS Mutations.
    Lei L; Wang WX; Yu ZY; Liang XB; Pan WW; Chen HF; Wang LP; Fang Y; Wang M; Xu CW; Fang MY
    Transl Oncol; 2020 Feb; 13(2):329-335. PubMed ID: 31881505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.
    Zhang P; Ma M; Nie J; Dai L; Hu W; Zhang J; Wu D; Chen X; Ma X; Tian G; Han S; Long J; Wang Y; Zhang Z; Hao Q; Fang J
    Heliyon; 2024 Feb; 10(4):e26026. PubMed ID: 38390071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.
    Kato Y; Udagawa H; Matsumoto S; Izumi H; Ohe Y; Kato T; Nishino K; Miyamoto S; Kawana S; Chikamori K; Shingyoji M; Sato Y; Takada Y; Toyozawa R; Azuma K; Tanaka Y; Sakai T; Shibata Y; Sugiyama E; Nosaki K; Zenke Y; Umemura S; Yoh K; Seike M; Goto K
    Lung Cancer; 2024 Nov; 197():107992. PubMed ID: 39423763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
    Gu X; Shi Z; Shao L; Zhang Y; Zhang Y; Song Z; Wang W; Lou G
    BMC Cancer; 2022 May; 22(1):576. PubMed ID: 35606756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Activity of Immune Checkpoint Inhibition in KRAS Mutated Non-small Cell Lung Cancer: A Single Centre Experience.
    Torralvo J; Friedlaender A; Achard V; Addeo A
    Cancer Genomics Proteomics; 2019; 16(6):577-582. PubMed ID: 31659111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment.
    Sun Y; Li Z; Jian H; Xia L; Lu S
    J Clin Med; 2022 Jul; 11(14):. PubMed ID: 35887766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
    Liu Y; Gao Y; Wang Y; Zhao C; Zhang Z; Li B; Zhang T
    BMC Cancer; 2022 Nov; 22(1):1175. PubMed ID: 36376839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
    Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
    Front Oncol; 2022; 12():974227. PubMed ID: 36523994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.